Choksi Asia Ltd

Choksi Asia maintains a strong liquidity position, with a current ratio of 4.61, indicating the company can cover its short-term obligations more than four times over. The company holds INR 99.9 million in cash and equivalents, which is a significant portion of its total assets of INR 471.8 million. The debt-to-equity ratio of 0.13 suggests a conservative capital structure, with long-term debt accounting for only INR 47.7 million against total equity of INR 368.8 million. In terms of profitability, Choksi Asia reports a return on equity (ROE) of 8.4% and a return on assets (ROA) of 6.57%. These figures are in line with the industry's preferred metrics, which emphasize asset efficiency and return generation. The company's net income of INR 30.99 million is supported by a gross profit of INR 65.29 million, translating to a gross margin of 17.66%. This margin is consistent with the industry's expectations for companies operating in the medical equipment and supplies sector. The company's revenue is concentrated in a few key product categories, including x-ray films, ultrasound and color doppler systems, and radiation shielding materials. While the input data does not provide a detailed breakdown of geographic exposure, the company's operations are primarily based in India, and its customer base is likely concentrated in the domestic healthcare market. This concentration may expose the company to regional economic and regulatory risks. Looking ahead, the company's growth trajectory appears to be modest. The input data does not provide specific revenue growth projections for the current or next fiscal year, but the company's operating cash flow of -INR 28.69 million suggests that it is currently investing in operations rather than generating positive cash flow. The capital expenditure of -INR 8.26 million indicates ongoing investment in the business, which could support future growth. The risk assessment for Choksi Asia indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's conservative capital structure and strong cash reserves reduce the likelihood of near-term dilution. However, the negative operating cash flow could be a concern if it persists, as it may indicate that the company is not generating sufficient cash to sustain its operations without external financing. Recent events, as reflected in the financial data, show that the company is maintaining a steady operational profile. The absence of significant changes in shares outstanding (both basic and diluted) suggests that there has been no recent equity issuance or dilution activity. The company's focus on job-work processing of x-ray films and its product diversification into ultrasound and NDT equipment may position it for future growth, but the current financial data does not indicate a strong upward trend.